Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$21.68M$21.68M+94.8% vs Q2 2019 Net Income-$2.33M-$2.33MN/M vs Q2 2019 EPS Diluted-$0.07-$0.07N/M vs Q2 2019 Operating Income$395,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,109,000N/M Margins · derivedOperating margin1.8%+169.7 pt vs Q2 2019
Net margin-10.8%+173.2 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 4, 2020 · 35 d after period end